Baiyao Technology, an AI virtual cell platform company, has secured tens of millions of yuan in a new funding round led by China Guo Xin Fund. The company utilizes AI to analyze and predict cellular behavior, aiming to revolutionize drug discovery and development by shifting from molecular-level to cell-level modeling. This funding will support the advancement of their AI algorithms, data platform, and industrial applications, positioning AIVC as a foundational infrastructure for life sciences. AI
IMPACT Accelerates AI adoption in drug discovery by enabling cell-level simulation and prediction, potentially reducing R&D costs and timelines.
RANK_REASON Funding round for an AI company with state-backed investment and novel technology. [lever_c_demoted from significant: ic=1 ai=1.0]
- AI virtual cell
- ARK Invest
- Baidu Ventures
- Baiyao Technology
- CellGraphCompass
- Cell Research
- China Guo Xin Fund
- Chinese Academy of Sciences
- DaoTong Capital
- Fengrui Capital
- GeneCompass
- Yunqi Capital
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →